We also treated the CSK- and PTEN-null OE19 cells with the PI3K inhibitor copanlisib (BAY 80–6946), a drug approved by the FDA for patients with relapsed follicular lymphoma [33]. The gene discussed is PIK3CA; the disease is follicular lymphoma.